| Name | Biotech Growth Trust (The) |
|---|---|
| Epic | BIOG |
| Isin | GB0000385517 |
| Index | MID300 |
| Industry | Closed End Investments |
| Latest share price | 1,145.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £256.55 | Debt ratio | n/a |
| Shares in issue | 22.49 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | |
| Dividend cover | n/a | EPS growth | |
| Earning per share | n/a | 52-week high / low | 620.00p / 1,146.10p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Biotech Growth Trust (The) |
|---|---|
| Address | One Wood Street, London,United Kingdom, EC2V 7WS |
| Telephone | |
| Website | http://www.biotechgt.com |
| Director | Position |
|---|---|
| Mr Julie Tankard | Non-Executive Director |
| Mr Geoffrey C Hsu | Non-Executive Director |
| Mr Roger Yates | Non-Executive Chairman |
| Mr Hamish Baillie | Senior Independent Director |
| Dr Nicola Shepherd | Independent Non-Executive Director |
| Mrs Julia Le Blan | Independent Non-Executive Director |
| Mr Lord David Willetts | Independent Non-Executive Director |
| Assets £ (m) | 2025 | 2024 | 2023 |
|---|---|---|---|
| Reporting date | 31/03/25 | 31/03/24 | 31/03/23 |
| Intangible asssets and goodwill | n/a | n/a | n/a |
| Investments and other non-current assets | |||
| Total non-current assets | |||
| Inventory / work in progress | |||
| Trade and other receivables | |||
| Cash and equivalents | 8.45 | 2.13 | 2.77 |
| Other current assets and asset held for resale | |||
| Total of all assets | 226.63 | 411.42 | 360.51 |
| Liabilities £ (m) | 2025 | 2024 | 2023 |
|---|---|---|---|
| Short term liabilities | |||
| Long term liabilities | |||
| Other liabilites / pension etc | |||
| Total of all liabilities | 5.42 | 50.11 | 30.22 |
| Net assets £ (m) | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net assets | 221.21 | 361.31 | 330.29 |
| Equity £ (m) | 2025 | 2024 | 2023 |
|---|---|---|---|
| Share capital | |||
| Minority interests | n/a | n/a | n/a |
| Retained earnings | |||
| Share premium account | 79.95 | 79.95 | 79.95 |
| Total equity |
| Income £ (m) | 2025 | 2024 | 2023 |
|---|---|---|---|
| Turnover | 1.11 | 1.2 | 0.31 |
| Operating profit | 0.2 | 0.31 | -0.56 |
| Pre-tax profit | 0.13 | 0.25 | -0.6 |